This is a $1,149,775.19 Firm Fixed Price Definitive Contract awarded by the Defense Health Agency to Spark Biomedical Inc., a small disadvantaged business, for an STTR Phase II effort to develop and test a military-grade wearable transcutaneous auricular neurostimulation device to restore performance after acute stress reaction. The contract is the result of a Small Business Technology Transfer (STTR) proposal titled "Development and Testing of a Military-Grade Wearable Transcutaneous Auricular Neurostimulation Device to Restore Performance After Acute Stress Reaction." The contract has an ultimate completion date of November 13, 2025 and was awarded on July 14, 2023. Spark Biomedical has previously received prime federal contracts and grants from the Department of Defense and National Institutes of Health for research, development, testing, and manufacturing of neuromodulation and bioelectronic medical devices, including for treatment of opioid withdrawal symptoms and Neonatal Opioid Withdrawal Syndrome.
Generated 9/19/24, 9:15 AM